Remarkable Results for Targeted Therapy of Rare CNS Tumors medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
The TRK inhibitor larotrectinib (Vitrakvi) showed activity in patients with TRK fusion-positive primary central nervous system (CNS) tumors, according to an analysis of two trials.
Among 33 patients with primary CNS tumors, the median overall survival (OS) had not been reached over 16.5 months of follow-up, and the 1-year OS rate was 85%, reported Sébastien Perreault, MD, of CHU Sainte-Justine University Hospital in Montreal.
The median progression-free survival (PFS) was 18.3 months, and the 1-year PFS rate was 56%.
Larotrectinib is active in this population with a high unmet need for tolerable targeted therapeutic options, Perreault said during a presentation at the virtual American Society of Clinical Oncology (ASCO) annual meeting.